Fewer service disruptions expected in Quebec's health-care network this summer
But some regions such as the Mauricie, Centre-du-Québec, the Laurentians, Bas-Saint-Laurent and Côte-Nord remain under surveillance, said Robin Marie Coleman, Santé Québec's assistant vice-president of access and care pathway co-ordination.
"The teams at Santé Québec's head office have deployed a new tracking tool that will provide us to have a real-time picture of how things are going everywhere in the province in order to be able to provide support when needed," she said.
Coleman explained that, historically, the pressure on health-care services increases between mid-June and the beginning of September — mainly due to staff vacations and tourism across Quebec.
According to her, 80 per cent of service disruptions have been avoided so far for the summer season.
For the remaining disruptions, 90 per cent already have measures that have been identified or implemented to try and avoid them, said Véronique Wilson, general manager of network co-ordination and operations support at Santé Québec.
To manage interruptions, Wilson added, the Crown corporation plans to set up service corridors between regions, transfer patients to other hospitals, request support from employees in other regions and deploy a "public flying squad" — which consists of 246 employees working primarily in remote areas to maintain access to health-care.
Julie Delaney, director of the CISSS des Laurentides, presented the plan for her region to reporters.
Among the initiatives in Delaney's plan are massive recruitment efforts and the opening of 2.5 additional operating rooms per day — which could mean 300 to 350 more surgeries this summer than last. Every region in the province has a plan tailored to their local realities.
Provincial summer planning began in March.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Quebec wants to launch AI pilot project to take medical notes in 2026
Emergency room physician Dr. Olivier Lavigueur works on a computer while providing care for patients in the emergency room at the Humber River Hospital during the COVID-19 pandemic in Toronto on Tuesday, January 25, 2022. (THE CANADIAN PRESS/Nathan Denette) More and more health care professionals are using artificial intelligence (AI) to transcribe medical notes during patient consultations, and Quebec's health ministry is planning to jump on the bandwagon. Work is underway to evaluate available solutions for clinical and non-clinical notetaking, Santé Québec said in an email to The Canadian Press. Currently, only solutions that have obtained official certification from Santé Québec, among other criteria to guarantee patient data protection, can be used in the health care network. Plume IA and CoeurWay are among the Quebec companies attracting more doctors to their applications. For now, Plume IA mainly does business with family medicine groups (GMFs). The company is currently in the process of having its application tested by speech therapists, social workers, doctors and nurses 'to demonstrate that it works' and eventually obtain 'a licence for an entire department, for an entire hospital,' said Plume IA Co-Founder Dr. James Tu. He launched Plume IA with Dr. Jasmin Landry one year ago, and says about 10 per cent of Quebec's doctors are already using their app – about 2,000 doctors. 'The feedback we've gotten has been really encouraging,' said Tu. 'Doctors call us, they write to us, they say we've changed their practice, they go home much less tired, they have more time with their families. We have stories of family doctors who have postponed their retirement this year because they found that the workload had decreased and that it brought back some enjoyment to their work.' Tu is an emergency physician and estimates that in his practice, he is able to see four to six more patients in an eight-hour shift. The amount of time saved varies depending on the practice, but in general, health care professionals can save one to two hours of charting per day. 'The app is accessible and works for all specialties,' said Tu. 'Those who get the most value from our app are those who have to do a lot of writing. I'm thinking in particular of social workers who have to write notes on patient demographics and psychosocial issues.' Proofread, validate and insert The Plume AI app has two modes. The first involves recording a discussion during a consultation with a patient (after obtaining their consent). The app then transforms the discussion into a structured medical note, a step that clinicians are used to doing themselves. The doctor can also conduct a consultation as normal and then, at the end, record themselves talking to the app to produce the same kind of structured medical note. According to Tu, even if a patient has a strong accent or uses certain phrases in another language, the app will be able to produce a reliable medical note. 'That's the power of artificial intelligence: it's not necessarily a word-for-word transcription. It's the artificial intelligence that interprets the conversation [...] and is able to deduce a little more about the context,' Tu points out. He acknowledges that occasionally, some errors may still slip into the note, and that clinicians need to be vigilant. 'I think it's a habit that everyone has anyway, instinctively rereading the note and correcting any typos or adding information that is more visual or implicit. Then they can correct the note directly in the app. It takes a few seconds, and then they can immediately validate it and insert it into their file,' explained Tu. For now, Plume IA is focusing solely on transcription, but its co-founder says he is confident that the technology will one day advance the accuracy and speed of diagnoses. 'The potential is almost endless, and I think it will happen,' he said. However, Tu notes that important issues must still be addressed, including ethical questions, accountability, and the diversity of data sources. The Canadian Press's health coverage is supported by a partnership with the Canadian Medical Association. The Canadian Press is solely responsible for this journalistic content. This report by The Canadian Press was first published in French on Aug. 11, 2025.
National Post
31-07-2025
- National Post
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development
Article content LAVAL, Québec — Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation ('VoxCell'), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials. Article content This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment. By integrating VoxCell's high-resolution 3D bioprinted tissue platforms into Altasciences' discovery and preclinical services, both companies aim to reduce R&D timelines and increase the success rate of investigational therapies. Article content 'We're proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,' Article content said Steve Mason, Co-Chief Operating Officer at Altasciences. Article content 'This collaboration aligns with our commitment to the 3Rs as well as to innovative, efficient solutions that improve data quality and accelerate decisions for our clients.' Article content VoxCell's proprietary bioprinted tissues are engineered to closely mimic the complexity of human tumors and other biological structures, offering drug developers an advanced platform for evaluating efficacy, safety, and toxicity—before moving into animal or human studies. Article content 'Our mission has always been to make drug screening more human-relevant and predictive,' Article content said Karolina Valente, CEO of VoxCell BioInnovation. Article content 'Altasciences shares this forward-thinking approach, and we're excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions.' Article content The collaboration will focus initially on drug screening for ocular indications, with plans to expand into additional therapeutic areas and applications. Article content This partnership represents a shared vision: to transform early-stage research through innovation, integration, and smarter science—delivering better outcomes for patients worldwide. Article content About Altasciences Article content Altasciences Article content preclinical Article content and Article content clinical pharmacology Article content studies, including Article content formulation, manufacturing, and analytical services Article content . For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include Article content , Article content clinical pharmacology and proof of concept Article content , Article content bioanalysis Article content , program management, Article content research support Article content , medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Article content . Article content About VoxCell BioInnovation Article content VoxCell BioInnovation Article content is a biotechnology startup founded in 2020 in Victoria, British Columbia, Canada. The company is dedicated to advancing the future of in vitro modeling by creating novel testing platforms for oncology research and drug development. Article content VoxCell develop 3D bioprinted vascularized human-like tissue models that closely replicate native biology, offering a powerful tool for predictive, physiologically relevant research. Using a proprietary high-resolution bioprinter, advanced vascularization software, and Universal Bioinks™, they produce complex tissue models that mirror patient biopsy samples in structure and function. Article content Article content Article content Article content Contacts Article content Article content
CBC
17-07-2025
- CBC
New leader coming to Winnipeg's infectious disease lab
A new leader is coming to the National Microbiology Laboratory in Winnipeg, after its head stepped down just months after taking over leadership of the embattled laboratory that was previously at the centre of a security scandal involving a Chinese scientist. Microbiologist Jean Longtin will leave his position as vice-president of the laboratory on July 25, less than six months after taking on the role, and has accepted a position with Santé Québec that will begin in August, a spokesperson for Health Canada confirmed in an email Thursday. Health Canada also confirmed that Jason Kindrachuk, Canada Research Chair in the Molecular Pathogenesis of Emerging Viruses and an associate professor at the University of Manitoba Max Rady College of Medicine, will join the agency as the new vice-president of the lab beginning later this month. When Longtin took the reins of the federally run laboratory in January, he was tasked with implementing recommendations of the special committee on the Canada-China relationship. Those recommendations stemmed from concerns about Chinese espionage. In 2019, two Canadian researchers of Chinese origin, Xiangguo Qiu and her husband, Keding Cheng, were escorted out of the lab before later being fired. Declassified Canadian Security Intelligence Service documents tabled in the House of Commons in February 2024 said the couple provided confidential scientific information to China and posed a credible security threat to the country. The federal government said Longtin decided to take a role in Quebec to be closer to his family. Kindrachuk, who will begin his new role as head of the lab on July 28, has "significant experience in the areas of biochemistry and infectious diseases, and an extensive track record of scientific research," Health Canada said. His research has focused on the circulation, transmission and pathogenesis of emerging viruses that pose the greatest threat to global human and animal health, including Ebola viruses, coronaviruses and influenza viruses, the University of Manitoba website says. The lab in Winnipeg is a biosafety Level 4 infectious disease laboratory, the only one of its kind in Canada, and with maximum containment, scientists at the lab are able to work with pathogens including Ebola, Marburg virus and Lassa fever, the federal government says.
